However the continued efforts to design potent and specific TGM2 inhibitors could provide exciting opportunities over the coming years to disrupt aberrant BECN1 aggresome formation, restoring normal autophagy, and potentially significantly ameliorating persistent infections and inflammation in CF airways. This evidence concerns the gene BECN1 and cystic fibrosis.